Skip to content
OpenCapital
Get started

Fate Therapeutics FATE Q1 2026 earnings

Reported May 13, 2026 · Before market open

Revenue$1.3MMiss by $192.9KDiluted EPS-$0.26Beat by $0.03
Revenue estimate$1.5M
EPS estimate-$0.29

Next report

Aug 11, 2026 (In 4 weeks)
Revenue estimate$1.4M
EPS estimate-$0.28

Versus estimates

Revenue

Q1 2026$1.3MMiss by $192.9K
Q4 2025$1.4MBeat by $32.4KQ3 2025$1.7MBeat by $542.9KQ2 2025$1.9MBeat by $758.1KQ1 2025$1.6MBeat by $444.6KQ4 2024$1.9MBeat by $291.3K

Diluted EPS

Q1 2026-$0.26Beat by $0.03
Q4 2025-$0.27In lineQ3 2025-$0.27Beat by $0.02Q2 2025-$0.29Beat by $0.06Q1 2025-$0.32Beat by $0.07Q4 2024-$0.31Beat by $0.13

Ask the moment Fate Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Fate Therapeutics report Q1 2026 earnings?
Fate Therapeutics (FATE) reported Q1 2026 earnings on May 13, 2026 before market open.
What were Fate Therapeutics's Q1 2026 revenue and EPS?
Fate Therapeutics reported revenue of $1.3M and diluted EPS of $-0.26 for Q1 2026.
Did Fate Therapeutics beat estimates in Q1 2026?
Revenue missed the consensus estimate of $1.5M by $192.9K. EPS beat the consensus estimate of $-0.29 by $0.03.
How did Fate Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 20.3% from $1.6M a year earlier and diluted EPS grew 18.8% from $-0.32.
Where can I find Fate Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-220691) and the 10-Q periodic report (0001193125-26-220696) directly on SEC EDGAR. The filing index links above go to sec.gov.